Drug Shortage Report for CASPOFUNGIN FOR INJECTION
Report ID | 169103 |
Drug Identification Number | 02486997 |
Brand name | CASPOFUNGIN FOR INJECTION |
Common or Proper name | CASPOFUNGIN FOR INJECTION |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | CASPOFUNGIN |
Strength(s) | 70MG |
Dosage form(s) | POWDER FOR SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 70 mg |
ATC code | J02AX |
ATC description | ANTIMYCOTICS FOR SYSTEMIC USE |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2022-11-01 |
Actual start date | 2022-11-01 |
Estimated end date | 2023-01-23 |
Actual end date | 2023-01-23 |
Shortage status | Resolved |
Updated date | 2023-01-26 |
Company comments | We will be encountering a supply interruption on our Caspofungin for Injection 70 mg Vial 10 mL effective November 1, 2022 until January 23, 2023. Per our communication dated July 17, 2022, please note all current inventory of this product expires October 31, 2022. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v5 | 2023-01-26 | French | Compare |
v4 | 2023-01-26 | English | Compare |
v3 | 2022-11-02 | English | Compare |
v2 | 2022-09-12 | French | Compare |
v1 | 2022-09-12 | English | Compare |
Showing 1 to 5 of 5